GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (XCNQ:ACOG) » Definitions » ROCE %

Alpha Cognition (XCNQ:ACOG) ROCE % : -91.47% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alpha Cognition's annualized ROCE % for the quarter that ended in Dec. 2024 was -91.47%.


Alpha Cognition ROCE % Historical Data

The historical data trend for Alpha Cognition's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition ROCE % Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
-103.18 -238.62 -255.96 - -61.19

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3,459.82 -919.77 -553.42 -91.47

Alpha Cognition ROCE % Calculation

Alpha Cognition's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-20.588/( ( (3.29 - 3.51) + (72.285 - 4.774) )/ 2 )
=-20.588/( (-0.22+67.511)/ 2 )
=-20.588/33.6455
=-61.19 %

Alpha Cognition's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=-32.128/( ( (6.811 - 4.072) + (72.285 - 4.774) )/ 2 )
=-32.128/( ( 2.739 + 67.511 )/ 2 )
=-32.128/35.125
=-91.47 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Cognition  (XCNQ:ACOG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Alpha Cognition ROCE % Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Cognition Business Description

Traded in Other Exchanges
Address
c/o 1200 – 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
Executives
John P. Havens Director